CN104114545B - 用于制备非布索坦多晶型物的方法 - Google Patents

用于制备非布索坦多晶型物的方法 Download PDF

Info

Publication number
CN104114545B
CN104114545B CN201280066457.1A CN201280066457A CN104114545B CN 104114545 B CN104114545 B CN 104114545B CN 201280066457 A CN201280066457 A CN 201280066457A CN 104114545 B CN104114545 B CN 104114545B
Authority
CN
China
Prior art keywords
febuxostat
solvent
acid
ester
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280066457.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104114545A (zh
Inventor
拉马科特斯瓦拉·劳·耶蒂
巴拉克里希纳·雷迪·博加拉
萨蒂什·贝拉韦利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of CN104114545A publication Critical patent/CN104114545A/zh
Application granted granted Critical
Publication of CN104114545B publication Critical patent/CN104114545B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280066457.1A 2011-11-15 2012-11-14 用于制备非布索坦多晶型物的方法 Expired - Fee Related CN104114545B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3909/CHE/2011 2011-11-15
IN3909CH2011 2011-11-15
PCT/IN2012/000748 WO2013076738A2 (en) 2011-11-15 2012-11-14 Process for the preparation of febuxostat polymorphs

Publications (2)

Publication Number Publication Date
CN104114545A CN104114545A (zh) 2014-10-22
CN104114545B true CN104114545B (zh) 2018-06-01

Family

ID=47710247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280066457.1A Expired - Fee Related CN104114545B (zh) 2011-11-15 2012-11-14 用于制备非布索坦多晶型物的方法

Country Status (7)

Country Link
US (1) US20140283486A1 (https=)
EP (1) EP2780335B1 (https=)
JP (1) JP2014533297A (https=)
CN (1) CN104114545B (https=)
AU (1) AU2012342011A1 (https=)
CA (1) CA2855923A1 (https=)
WO (1) WO2013076738A2 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
CN101085761A (zh) * 2007-06-29 2007-12-12 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101768150A (zh) * 2009-01-05 2010-07-07 北京利乐生制药科技有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
WO2011101867A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566652C (en) 1998-06-19 2008-10-21 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
CN101139325B (zh) * 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN101412700B (zh) * 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101386605B (zh) * 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
CN101759656B (zh) * 2008-12-12 2013-04-03 重庆医药工业研究院有限责任公司 非布司他新晶型及其制备方法
CN101857578A (zh) * 2009-04-08 2010-10-13 北京海步国际医药科技发展有限公司 非布司他新晶型及制备方法
ES2395381T3 (es) 2009-06-10 2013-02-12 Teva Pharmaceutical Industries Ltd. Formas cristalinas de Febuxostat
CN101817801A (zh) * 2009-08-12 2010-09-01 北京红惠新医药科技有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸新晶型k及其他晶型的制备方法
CN101671315B (zh) * 2009-08-19 2011-06-22 何广卫 非布索坦的新晶型及其制备方法
WO2011080651A2 (en) 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Polymorphic forms of febuxostat
AU2011222462A1 (en) * 2010-03-04 2012-09-27 Ranbaxy Laboratories Limited Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
EP2563768A4 (en) * 2010-04-29 2013-07-31 Reddys Lab Ltd Dr MANUFACTURE OF FEBUXOSTAT
TW201217347A (en) * 2010-07-13 2012-05-01 Interquim Sa Process for preparing the crystalline form a of febuxostat
AR081267A1 (es) * 2010-07-13 2012-07-18 Interquim Sa Procedimiento de obtencion de la forma cristalina a del febuxostat
AU2012241378A1 (en) * 2011-04-15 2013-10-31 Sun Pharmaceutical Industries Limited Febuxostat solid dispersion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
CN101085761A (zh) * 2007-06-29 2007-12-12 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101768150A (zh) * 2009-01-05 2010-07-07 北京利乐生制药科技有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
WO2011101867A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof

Also Published As

Publication number Publication date
NZ625043A (en) 2016-06-24
US20140283486A1 (en) 2014-09-25
WO2013076738A3 (en) 2013-10-10
CN104114545A (zh) 2014-10-22
JP2014533297A (ja) 2014-12-11
EP2780335B1 (en) 2019-04-10
CA2855923A1 (en) 2013-05-30
WO2013076738A2 (en) 2013-05-30
EP2780335A2 (en) 2014-09-24
AU2012342011A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
JP5889275B2 (ja) ラルテグラビル塩およびその結晶形
US20090192200A1 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
CA2958139A1 (en) Solid state forms of ibrutinib
US8901322B2 (en) Crystalline forms of cabazitaxel and process for preparation thereof
CN102295655A (zh) 一种氧头孢烯类抗菌素中间体溶剂化物及其制备方法
WO2018158697A1 (en) A process for the preparation of ixazomib citrate
CN104114545B (zh) 用于制备非布索坦多晶型物的方法
EP3286168A1 (en) A solid form of apremilast and a process for preparing the same
EP2231613B1 (en) Montelukast benzhydryl piperazine salts and process for preparation thereof
US9409913B2 (en) Polymorphic forms of alcaftadine
JP2960790B2 (ja) 経口投与用セファロスポリン水和物結晶
WO2015122702A1 (en) Novel crystalline form of bortezomib and preparation method thereof
JP2025501596A (ja) 酸化型グルタチオン及びその結晶形並びに不純物の調製方法
US20180273490A1 (en) Process for the Preparation of Eltrombopag Olamine
JPWO2023058645A5 (https=)
WO2010089753A2 (en) Novel polymorphs of lopinavir
WO2020174408A9 (en) Solid state forms of siponimod
MX2007010931A (es) Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
NZ625043B2 (en) Process for the preparation of febuxostat polymorphs
JP2011051896A (ja) Ｎ−シクロプロピル−３−アミノ−２−ヒドロキシヘキサン酸アミド塩酸塩の製造方法
JPH0641066A (ja) ピロール誘導体の製造方法
EP3684770A1 (en) Salts and solid state forms of larotrectinib
WO2008062480A2 (en) An improved process for the preparation of rimonabant
CN101583272A (zh) 取代的苯并噻吩化合物的盐形式
US20190337932A1 (en) Process for preparation of daclatasvir and salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180601

Termination date: 20181114

CF01 Termination of patent right due to non-payment of annual fee